Probiodrug AG has transferred its experimental cyclin-dependent kinase 9 (CDK9) inhibitor program to AstraZeneca. AstraZeneca has also purchased a lead molecule and back-up compounds along with the associated intellectual property. Financial terms were not disclosed. CDK9 has been tied to the regulation of genes involved in proliferation and inflammation, and has been shown to be a promising target for the treatment of cancer and inflammatory diseases. Cyclin-dependent kinases (CDKs) are regula...